HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Legend Biotech (NASDAQ:LEGN) and maintained a price target of $73.
June 06, 2024 | 10:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Legend Biotech and maintained a price target of $73, indicating continued confidence in the company's growth prospects.
The reiteration of a Buy rating and maintenance of a $73 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors, suggesting confidence in Legend Biotech's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100